When is ORKA's next earnings date?

Based on SEC filing cadence, Oruka Therapeutics Inc. (ORKA)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ORKA stock expected to move on earnings?

Volatility modeling currently projects a ±10.3% event move for ORKA, spanning a range between $85.6 and $105.26.

Stock Ratings / Health Care / ORKA / earnings

LNTH (76) NEOG (47) CLDX (29) NTLA (25) ⌘ Pro Terminal →

Oruka Therapeutics Inc. (ORKA) Next Earnings Date & Expected ±10.3% Move

$95.43 -1.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $94.99

Oruka Therapeutics Inc. (ORKA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $6.41B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORKA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Oruka Therapeutics Inc. (NASDAQ: ORKA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $95.43 (-1.49% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ORKA ranks #227 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORKA compare to LNTH and NEOG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ORKA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.8%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORKA?

▼

Per ORKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000907654), Oruka Therapeutics Inc. generated $341.7M in revenue (+38.5% YoY), -$105.4M in net income, and -$88.4M in free cash flow against $488.6M in total assets and $7.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $94.99 (-0.46%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-2.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORKA)Realized 20D OHLCV Swing Band: ±10.3%

Deterministic 5-Pillar Attribution (53/100 Composite)

🔍 WHY ORKA SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (32% of score)

20D Institutional Volume Accumulation (±10.3% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$76.68+4.2% Next Q

Q2 (-2Q)

Grade D$79.92+20.1% Next Q

Q3 (-1Q)

Grade C-$95.97-0.6% Next Q

Current

Grade D+$95.43-0.9% Hist 90D α

Trajectory: D (45) → D+ (53)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORKA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORKA currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($88.03) and Max Pain ($100.20) forces dealer call-delta covering toward $121.30.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORKA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ORKA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 53%NO 47%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±10.3% Swing Band

±$9.83 Expected Swing

MODEL EARNINGS SETUP GAUGE

ORKA Quantitative Pre-Earnings Setup: 53/100

Trailing EPS: $-1.59 • YoY Revenue Growth: -4.4%

Model Bullish Setup (53/100)Model Risk Weight (47/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$341.7M	-$105.4M	-$88.4M	52%
FY 2024	2024-12-31	$246.7M	-$83.7M	-$58.0M	52%
FY 2023	2023-12-31	$20.4M	-$5.3M	-$5.0M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORKA)

✓Walkthrough of ORKA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ORKA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.59%⚡ TESTING RESISTANCE

2026-11-03O $96.65H $96.87L $95.43C $95.43VOL 634.1K

RES: $97.55SUP: $64.39SMA50: $88.03SMA200: $70.19

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORKA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORKA Butterfly Map → + Track ORKA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

21.4%/yr Implied 5Y Growth

vs. -4.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ORKA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORKA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ORKA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORKA)

Health Care Rank #227 of 1016 ⚔️ LNTH vs ORKA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORKA vs. LNTH, NEOG, CLDX, NTLA)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Oruka Therapeutics Inc. (ORKA) ranks #227 by composite RQD confidence (53/100, grade D+) and #140 by equity capitalization ($6.41B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ORKA at 53/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ORKA ACTIVE Oruka Therapeutics Inc.	D+	53/100	—	—	-18.8%	-1.49%	$6.41B	Benchmark Subject
LNTH Lantheus Holdings Inc.	B+	76/100	28.0x	61.1%	20.3%	-0.15%	$6.56B	/lnth-vs-orka →
NEOG Neogen Corporation	D	47/100	—	46.9%	-0.6%	0.00%	$2.58B	/neog-vs-orka →
CLDX Celldex Therapeutics Inc.	E	29/100	—	87.1%	-35.0%	-3.52%	$2.36B	/cldx-vs-orka →
NTLA Intellia Therapeutics Inc.	E	25/100	—	—	-35.0%	-6.50%	$1.75B	/ntla-vs-orka →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000907654

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oruka Therapeutics Inc. (ORKA) reported GAAP revenue of $341.7M (+38.5% vs. FY2024 revenue of $246.7M , and +1572.8% cumulative change since FY2023) , GAAP net income of -$105.4M, operating cash flow of -$88.2M, and free cash flow of -$88.4M (-52.4% YoY). On the balance sheet, ORKA closed FY2025 with $488.6M in total assets against $7.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$341.7M	-$105.4M	-$88.2M	-$88.4M	$488.6M	$7.5M
FY2024 (FY)	2024-12-31	$246.7M	-$83.7M	-$57.8M	-$58.0M	$396.0M	$6.2M
FY2023 (FY)	2023-12-31	$20.4M	-$5.3M	-$5.0M	-$5.0M	$3.52B	$823.6M

3. ORKA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORKA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ORKA compare to LNTH and NEOG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ORKA?

Where is ORKA trading relative to its 50-day, 200-day, and 52-week technical levels?

ORKA last traded at $95.43 (-1.49% on volume of 654,389 shares), positioning the stock +8.41% above its 50-day simple moving average ($88.03) and +35.96% above its 200-day simple moving average ($70.19). Across its 52-week range of $25.23 to $115.52, ORKA sits at the 77.7% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.3% ($85.60 to $105.26).

Direct Sub-Reports: ORKA RQD Cockpit ORKA 12M Forecast ORKA Earnings & Move ORKA Dividends & DRIP ORKA Insiders & 13F ORKA Whale Options ORKA Profit Sankey ORKA News & Why

ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ORKA — Oruka Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:19:06Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ORKA carries an RQD Score of 53, letter grade D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars: Fundamental Cash Engine scores 7 of 20 (ROIC -18.8%; FCF yield -1.38%), indicating weak cash generation. Whale 13F Flow scores 17 of 20, the strongest pillar, reflecting institutional accumulation and options positioning. Insider Conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), a weak reading. Macro Regime Fit scores 10 of 20 (Beta 1.13; sector sensitivity), a middling reading. Forensic Balance Sheet scores 14 of 20 (Altman Z 26; Piotroski F 4/9; Debt/Equity 0.01), which is comparatively sound.

For a prospective investor, the rating's central message is that institutional positioning is supportive while the company's own cash economics and insider signals are weak. Upside drivers cited in the source data are primarily the institutional flow and the balance-sheet strength. The principal valuation tradeoff is that the stock trades at a Forward P/E of 28 while reported EPS (TTM) is -1.59 and operating margin is -6.8%, so the current price is not supported by reported earnings. The balance sheet's low leverage reduces solvency concern but does not address the negative free cash flow.

2. Business Model, Unit Margins & SEC Financial Trajectory

Oruka Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under the industry Biotechnology: In Vitro & In Vivo Diagnostic Substances. Gross margin is recorded as 0% in the market data.

Operating and net losses widened from FY 2023 to FY 2025, and free cash flow was negative in every reported period. Per the market data, the operating margin is -6.8%, the net margin is -5.9%, and ROIC is -18.8%. The Altman Z-Score is 26, the Piotroski F-Score is 4 of 9, and the Debt/Equity ratio is 0.01, which together describe a lowly levered balance sheet with weak fundamental quality. Reported cash declined from $61.6M (FY 2024) to $46.9M (FY 2025), and the FY 2023 debt figure of $823.6M differs sharply from the $7.5M reported for FY 2025.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting the balance sheet. With Fundamental Cash Engine at 7/20 (ROIC -18.8%, FCF yield -1.38%) and Institutional Whale Flow at 17/20, sustained execution supports upside toward the top of the $25.23 – $115.52 52-week range.
🐻 Primary Bear Case: Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%. Investors must weigh current valuation against -6.8% operating margins and a 1.13 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ORKA carries a macro regime beta of 1.13 and gross margin of —.

Key Question #1: What is the basis for the psoriasis trial results referenced in the news, and what are their stated next steps?
Key Question #2: Why does reported debt decline from $823.6M (FY 2023) to $7.5M (FY 2025), and what drove the change?
Key Question #3: What explains the 52-week range of $25.23 to $115.52, and what drove the price movement?

ORKA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Oruka Therapeutics Inc. (ORKA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORKA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance Singapore • 20h ago

Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history

Yahoo Finance Singapore report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 23h ago

Oruka Therapeutics: The Psoriasis Market Becoming A Barbell, And ORKA-001 Owns The Far End

Seeking Alpha report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Oruka Therapeutics, Inc. Estimates – NASDAQ:ORKA

TradingView report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Benzinga • 1d ago

Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA)

Benzinga report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead

The Motley Fool report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results

Yahoo Finance report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Trial Success Might Change The Case For Investing In Oruka Therapeutics Stock (ORKA)

Simply Wall St report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A proposed 21,000-share sale at Oruka Therapeutics (ORKA) involves officer Joana Goncalves.

Stock Titan report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORKA Bull vs. Bear Conversation Board — What's Your Call at $95.43?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORKA 🐻 33% BEARISH CONVICTION

CA CashFlowKing FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $112.37 (+16.0%)

📌 Pinned Debate

Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting th

Picked up a starter position in ORKA in my $100K Virtual Cash book at $96.87. Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting the balance sheet.. Trading inside a $25.23–$115.52 52-week range with -1.38% FCF yield gives solid downside support if Biotechnology: In Vitro & In Vivo Diagnostic Substances multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 53/100 quality, though with 1.13 beta I'm scaling in with half-size at $96.87 and keeping dry powder in case we test $90.09.

RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH 🎯 Target: $73.62 (-24.0%)

Spot @ $96.87

Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%.

Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%.. Look at the math on ORKA: paying 28.0x forward P/E for -18.8% ROIC and -6.8% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $85.25 before getting long.